Semaglutide access in India faces significant cost barriers, raising critical questions for children and special populations

India faces a growing public health challenge with obesity affecting approximately 33-46% of its population, a major risk factor for several non-communicable diseases. While semaglutide, a potent glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated superior efficacy in obesity management, its high cost presents a formidable barrier to access. This economic disparity creates a significant gap, preventing a large segment of the population from benefiting from this proven treatment, thereby exacerbating health inequities and hindering national efforts against metabolic disease.

This paper functions as a commentary and review, examining the current landscape of semaglutide access within India. It critically analyzes the existing socioeconomic barriers, primarily the prohibitive cost, that limit its widespread availability. The authors did not conduct an experimental study but rather synthesized observations and highlighted critical gaps in knowledge concerning semaglutide's application and safety in specific, vulnerable patient demographics, such as children and other special populations, identifying areas for urgent future research.

The review highlights that obesity impacts a substantial 33-46% of the Indian population, underscoring the urgent need for effective interventions like semaglutide. Despite semaglutide's proven efficacy as a GLP-1 receptor agonist, its high cost is identified as the primary impediment to access, particularly for individuals with lower incomes. This mirrors global trends where higher-income earners with private health insurance are considerably more likely to utilize semaglutide, as evidenced by MEPS 2022 data analysis. The authors emphasize that this cost barrier effectively negates the public health benefit of an otherwise highly effective medication.

The paper specifically identifies critical unanswered questions regarding semaglutide use in children and other special populations, indicating a significant and concerning knowledge gap for these vulnerable groups.